Lindsay G S Bengtson

4PUBLICATIONS
8CO-AUTHORS
Medical virologyClinical chemistry (incl. diagnostics)NanomedicineCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 01, 2025
Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL.

Sanjay Sethi, Brendan Clark, Erin K Buysman

|Mar 31, 2023
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.

Nicola A Hanania, Scott H Bunner, Lindsay G S Bengtson

|Mar 24, 2022
Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.

David Singer, Lindsay G S Bengtson, Craig S Conoscenti

|May 09, 2018
Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.

Lindsay G S Bengtson, Michael DePietro, Jeffrey McPheeters

Pageof 1

Frequent Collaborators

1 joint publications

Nicola A Hanania

1 joint publications

Scott H Bunner

1 joint publications

Afisi S Ismaila

1 joint publications

Michael Bogart